AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
2.890
+0.160 (5.86%)
At close: Nov 4, 2024, 4:00 PM
2.660
-0.230 (-7.96%)
Pre-market: Nov 5, 2024, 6:26 AM EST
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 11, with a low estimate of 5.00 and a high estimate of 17. The average target predicts an increase of 280.62% from the current stock price of 2.89.
Analyst Consensus: Buy
* Price targets were last updated on Jul 11, 2024.
Analyst Ratings
The average analyst rating for ABCL stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Benchmark | Benchmark | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2024 |
| Keybanc | Keybanc | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +73.01% | Jul 11, 2024 |
| Keybanc | Keybanc | Buy Maintains $8 → $7 | Buy | Maintains | $8 → $7 | +142.21% | May 8, 2024 |
| Benchmark | Benchmark | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Feb 22, 2024 |
| Stifel | Stifel | Strong Buy Maintains $21 → $17 | Strong Buy | Maintains | $21 → $17 | +488.24% | Feb 21, 2024 |
Financial Forecast
Revenue This Year
34.27M
from 38.03M
Decreased by -9.88%
Revenue Next Year
49.59M
from 34.27M
Increased by 44.70%
EPS This Year
-0.59
from -0.51
EPS Next Year
-0.70
from -0.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 42.0M | 98.7M | 180.8M | ||
| Avg | 34.3M | 49.6M | 86.6M | ||
| Low | 26.9M | 21.6M | 32.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.5% | 188.0% | 264.6% | ||
| Avg | -9.9% | 44.7% | 74.6% | ||
| Low | -29.2% | -37.1% | -34.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.55 | -0.48 | -0.42 | ||
| Avg | -0.59 | -0.70 | -0.66 | ||
| Low | -0.63 | -0.82 | -0.79 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.